Ganetespib (STA-9090)

製品コードS1159

Ganetespib (STA-9090)化学構造

分子量(MW):364.4

Ganetespib (STA-9090)は一種のHSP90阻害剤で、OSA 8細胞の中にIC50値が4 nMですが、OSA細胞アポトーシスを誘導して、正常な造骨細胞に影響を与えません。Ganetespib (STA-9090)も一種のSTA-1474の活性代謝物です。臨床3期。

サイズ 価格(税別) 在庫  
JPY 50132.00 あり
JPY 44820.00 あり
JPY 61420.00 あり

カスタマーフィードバック(3)

  • Loss of viability (Z score) resulting from HSP90 inhibition (HSP90i; ganetespib, 5 nM) in FANCA null GM6914 cells transduced with retroviruses encoding FANCA wild-type (squares; WT) or empty vector control (circles; null) in the presence (black symbols) of MMC (31.6 nM) or DMSO control (gray symbols). Data from three independent experiments are presented as mean ± SEM.

    Cell, 2017, 168(5):856-866. Ganetespib (STA-9090) purchased from Selleck.

    Breast cancer (MDA-MB-231), pancreatic cancer (PaTu2), lung cancer (A549), colon cancer HCT-116, and acute myeloid leukemia (SKM1) cell lines were incubated with increasing amounts of PU-H71 and STA-9090 as indicated. Western blot analysis with PRKD2, cleaved PARP, and cleaved caspase-9 antibodies is depicted.

    Cancer Res 2014 10.1158/0008-5472.CAN-14-1017. Ganetespib (STA-9090) purchased from Selleck.

  • Western blot analysis of the expression of Brd4 and Hsp90 from whole-cell lysates of Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 at indicated concentrations for 24 h (B), and in Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 (200 nM) at indicated time points (C).

    Hum Mol Genet, 2015, 10.1093/hmg/ddv136. Ganetespib (STA-9090) purchased from Selleck.

製品安全説明書

HSP (e.g. HSP90)阻害剤の選択性比較

生物活性

製品説明 Ganetespib (STA-9090)は一種のHSP90阻害剤で、OSA 8細胞の中にIC50値が4 nMですが、OSA細胞アポトーシスを誘導して、正常な造骨細胞に影響を与えません。Ganetespib (STA-9090)も一種のSTA-1474の活性代謝物です。臨床3期。
ターゲット
HSP90 [1]
(OSA 8 cells)
4 nM
体外試験

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 Mo\wRZBweHSxc3nzJGF{e2G7 MnfYN|AwQDBxMUWwM|I2OCCwTR?= M1zUXVI1NzR6L{eyJIg> NFjT[GpqdmS3Y3XzJIRwe2ViZHXw[Y5l[W62IHnu[JVkfGmxbjDv[kBieG:ydH;zbZM> M{HNSlI2QDh{NUWw
MV411 NH\KZYdCeG:ydH;zbZMhSXO|YYm= MUOzNE85OC9zNUCvNlUxKG6P NHK3XYszPC92OD:3NkBp MmjRbY5lfWOnczDkc5NmKGSncHXu[IFvfCCrbnT1Z5Rqd25ib3[gZZBweHSxc3nz NF\UXWYzPTh6MkW1NC=>
MGC-803 M1Ti[2NmdGxiVnnhZoltcXS7IFHzd4F6 NInWNGIxNjFvMUCwNEBvVQ>? MUO3NkBp MYDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M{HQXlI2PTlyOEC1
SGC-7901 NFnDOYFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWGwMlEuOTByMDDuUS=> M3;hc|czKGh? MlPpbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M1\iXlI2PTlyOEC1
MKN-28 MlTlR4VtdCCYaXHibYxqfHliQYPzZZk> Mn63NE4yNTFyMECgcm0> M4Hhb|czKGh? MnvxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M2i0VlI2PTlyOEC1
MGC-803 M2rFfmZ2dmO2aX;uJGF{e2G7 NH3iW44xNjFvMUCwNEBvVQ>? NY\u[ZFkOjRiaB?= MmrxbY5lfWOnczDHNk9OKGOnbHytZ5lkdGViYYLy[ZN1 NITJXJYzPTV7MEiwOS=>
HCT-116 Mk\MSpVv[3Srb36gRZN{[Xl? M2jBNlUxdk1? MXuyOEBp NUnTUHpxTE2VTx?= MYHpcoR2[2WmIFewM2cyKGG{cnXzeC=> NVrVb3RpOjV{MUC3PVQ>
HT-29 NEPMbVhHfW6ldHnvckBCe3OjeR?= NGjD[Ho2OG6P NWPOSW5uOjRiaB?= NF3tWGFFVVOR NUfPOVYycW6mdXPl[EBIOC:JMTDhdpJme3R? NWPLcHFPOjV{MUC3PVQ>
SCC25 NHP5bmNEgXSxeHnjbZR6KEG|c3H5 MV[xNE82OCCwTR?= MojhNlQhcA>? NGLDR5hl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> MV6yOVIxPTR|MB?=
FUDA M4TybWN6fG:6aXPpeJkhSXO|YYm= Mli0NVAwPTBibl2= MlXxNlQhcA>? Mlv6[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5 NWqx[XN4OjV{MEW0N|A>
Detroit562 NF[3UGVEgXSxeHnjbZR6KEG|c3H5 MWCxNE82OCCwTR?= MV6yOEBp M2P1e4Rm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDk[ZBmdmSnboTsfS=> NUHH[Gt{OjV{MEW0N|A>
CAL27 MoDNR5l1d3irY3n0fUBCe3OjeR?= M1;LflExNzVyIH7N MUWyOEBp NWTMWWdW\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 MVSyOVIxPTR|MB?=
DSH1 NITRTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3qWYdvUUN3ME22JI5O M3XQWFI1Pzh2OEO5
SW-1710 M3LwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTZibl2= NEnjSpUzPDd6NEizPS=>
T24 MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PxNGlEPTB;NzDuUS=> NWLBVVhuOjR5OES4N|k>
RT112 MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\0cHF3UUN3ME25JI5O NYP4XHV[OjR5OES4N|k>
639-V MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrCTo1HUUN3ME2xNEBvVQ>? NV;GTYNPOjR5OES4N|k>
SCaBER NXvhWXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDYTWM2OD1zMDDuUS=> NWXYTII6OjR5OES4N|k>
BFTC NGLiWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF5IH7N M4\mUlI1Pzh2OEO5
J82 NV7O[FVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF6IH7N NVS5cFFEOjR5OES4N|k>
HT-1376 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTVcXVKSzVyPUKxJI5O MnXBNlQ4QDR6M{m=
647-V MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWyTWM2OD1{NzDuUS=> NVe2dWIzOjR5OES4N|k>
UM-UC3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrkbIZOUUN3ME2zN{BvVQ>? MlHvNlQ4QDR6M{m=
LB831-BLC MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvLdJhKSzVyPUO0JI5O MUmyOFc5PDh|OR?=
KU-19-19 NHH6WWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3wZm1KSzVyPUO2JI5O NIjDTVczPDd6NEizPS=>
35612 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H1VWlEPTB;M{igcm0> NYnFS|Q4OjR5OES4N|k>
5637 MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi5SZhKSzVyPUS0JI5O MkDzNlQ4QDR6M{m=
HT-1197 NHmzZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13SNmlEPTB;NUOgcm0> MXGyOFc5PDh|OR?=
MGH-U3 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTV|IH7N NU\o[pVuOjR5OES4N|k>
TCCSUP MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLJTnRUUUN3ME2xOFIhdk1? NV;CU|J5OjR5OES4N|k>
RT4 M4D0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPoTWM2OD1zN{OzJI5O M4jVXlI1Pzh2OEO5
SW780 NYjZWGp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETLeGtKSzVyPUO0OVEhdk1? NEfVeI8zPDd6NEizPS=>
RKO NHLmUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXXOWZKSzVyPUSgcm0> MWOyOFY5Ojd2Nx?=
LS-411 N NXS0RWhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnjRmxKSzVyPUWgcm0> MWOyOFY5Ojd2Nx?=
SW620 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGwfINPUUN3ME24JI5O MnrHNlQ3QDJ5NEe=
HCT-15 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTTTWM2OD16IH7N MYmyOFY5Ojd2Nx?=
HuTu-80 Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fHT2lEPTB;MUOgcm0> NX\wV|hTOjR4OEK3OFc>
HCT 116 NWe0cVlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zRdWlEPTB;MUSgcm0> NUnRTpJiOjR4OEK3OFc>
COLO-205 Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vJ[WlEPTB;MUSgcm0> NXLadGlbOjR4OEK3OFc>
NCI-H747 NFS1TJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF5IH7N M{L2eFI1Pjh{N{S3
COLO-678 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT2OGtEUUN3ME2yNUBvVQ>? M{fqTlI1Pjh{N{S3
LoVo NUH1NohoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJ{IH7N M3jESVI1Pjh{N{S3
LS-1034 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNzIH7N M4\mcVI1Pjh{N{S3
SNU-C2B M3TLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DONmlEPTB;NEWgcm0> NEXFSlAzPDZ6Mke0Oy=>
LS-123 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPpTWM2OD15MzDuUS=> NEO5TXEzPDZ6Mke0Oy=>
SK-CO-1 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRThzIH7N MYmyOFY5Ojd2Nx?=
HCC2998 M4[wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTJTWM2OD1zMkigcm0> MnfKNlQ3QDJ5NEe=
MDA-MB-231 NHjrephHfW6ldHnvckBCe3OjeR?= M2jRSVExOCCwTR?= NYLneYZEOzBibXnu NF7oWGVqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gTGlHNTIQsR?= MWGyOFI1QDJ4NR?=
MDA-MB-435 NYTDbWpXTnWwY4Tpc44hSXO|YYm= NXuwcGpQOTByIH7N MWizNEBucW5? NXThc3NJcW6qaXLpeJMh[WOldX31cIF1cW:wIH;mJGhKTi1zzsG= MofNNlQzPDh{NkW=
BT-20  MYXGeY5kfGmxbjDBd5NigQ>? M33VO|ExOC9{NUCgcm0> NX7ldY9qOjRiaB?= NHzFcpJz\XO3bITl[EBqdiCjIHTvd4Uu\GWyZX7k[Y51KGSnc4ThZoltcXqjdHnvckBw\iCHR1\SMEBKT0ZvSWKsJG1GXCxiYX7kJGNTSUZ? MXKyOFE4OzV2MR?=
MDA-MB-231 M2fFTmZ2dmO2aX;uJGF{e2G7 NGDWOFAyODBibl2= M1iwXlI1KGh? NF\OUVNqdmirYnn0d{B1cGVibXnndoF1d3K7IHHu[EBqdn[jc3n2[UBk[XCjY3n0feKh M1zVNFI1OTd|NUSx
H82 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;4Z2lEPTB;M{CuNlchdk1? MVuyOFE3PjVyNR?=
GLC4 M{jHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDVPFhsUUN3ME2yNE41PyCwTR?= NELVR|EzPDF4NkWwOS=>
H69 NVzNVpNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTh|LkO2JI5O MmXLNlQyPjZ3MEW=
H128 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LWNGlEPTB;NkmuOVUhdk1? Mn3iNlQyPjZ3MEW=
H146 M{i2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\RTWM2OD1{OD61NUBvVQ>? M4jQOlI1OTZ4NUC1
H187 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK5TWM2OD1{ND65PUBvVQ>? M{LFelI1OTZ4NUC1
H526 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjZSVdKSzVyPUKxMlY1KG6P NXT6XFJxOjRzNk[1NFU>
N592 M3nkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHK5OXpKSzVyPUG0MlEzKG6P MX[yOFE3PjVyNR?=
H620 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v2VGlEPTB;M{KuOlchdk1? NIPzXo0zPDF4NkWwOS=>
H792 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLnVmNmUUN3ME20OU4xPyCwTR?= NEeyXIwzPDF4NkWwOS=>
H1173 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXhPYd[UUN3ME2xNk43OiCwTR?= NFfnNIUzPDF4NkWwOS=>
AC3 Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorDTWM2OD1{NT65JI5O MlXxNlQyPjZ3MEW=
H82 NWfuN5N6TnWwY4Tpc44hSXO|YYm= MmnQN|Ahdk1? MoLQO|IhcA>? NGDXN2ZqdmS3Y3XzJJBmenOrc4TlcpQhTzJxTTDwbIF{\SCjcoLld5Q> NUnsXoRLOjRzNk[1NFU>
GLC4 Mk\pSpVv[3Srb36gRZN{[Xl? NHnBPVI{OCCwTR?= NGO3fYY4OiCq NIj3WmZqdmS3Y3XzJJBmenOrc4TlcpQhTzJxTTDwbIF{\SCjcoLld5Q> M4D0c|I1OTZ4NUC1
H146  MWnGeY5kfGmxbjDBd5NigQ>? MXqzNEBvVQ>? NHTpPYU4OiCq MmnYbY5lfWOnczDw[ZJ{cXO2ZX70JGczN01icHjhd4Uh[XK{ZYP0 NWm0flBOOjRzNk[1NFU>
OVCAR-5 M{\nXWNmdGxiVnnhZoltcXS7IFHzd4F6 MoDFNE0yODByIH7N MVO3NkBp NYe5UGRycW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NWrMUmZTOjN7MECxN|Y>
OVCAR-8 NGnOdoVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV7CcnVjOC1zMECwJI5O NV\hOVRGPzJiaB?= NELjT5dqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NV[zXmRCOjN7MECxN|Y>
A1847 NXnsRXVyS2WubDDWbYFjcWyrdImgRZN{[Xl? NV7wNXV3OC1zMECwJI5O NXvkbYZoPzJiaB?= NUL1fW9tcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NWHzOXVYOjN7MECxN|Y>
SKOV-3 MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV[wMVExODBibl2= M1z4T|czKGh? M1\yXYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NXj6ZlZDOjN7MECxN|Y>
OVCAR-5 NHOyOlZCeG:ydH;zbZMhSXO|YYm= NXXZeFV6OTBvMUCwJI5O M4fhcFI1NzR6L{eyJIg> NYDHR2dNcW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboTsfS=> MYSyN|kxODF|Nh?=
OVCAR-8 NILhcHNCeG:ydH;zbZMhSXO|YYm= NWH4NVBsOTBvMUCwJI5O NF7lOHUzPC92OD:3NkBp NES2TGVqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHHu[EBld3OnIHTldIVv\GWwdHz5 M4fifVI{QTByMUO2
A1847 NYP0S5IxSXCxcITvd4l{KEG|c3H5 M2n6OFExNTFyMDDuUS=> M{j4eVI1NzR6L{eyJIg> NXGzfYs1cW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboTsfS=> NYGzO5RuOjN7MECxN|Y>
H2228 Mln0R4VtdCCYaXHibYxqfHliQYPzZZk> NVnCeZZ3OC1zMECwJI5O MU[3NkBp MkTBTWM2OD1zMzDuUS=> Ml3zNlM2OzN{NkW=
H3122 M3zkfmNmdGxiVnnhZoltcXS7IFHzd4F6 MkDLNE0yODByIH7N MWW3NkBp NH\qc4FKSzVyPUGwJI5O MYGyN|U{OzJ4NR?=
K008 NEnLSVhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3foVmlEPTB;NkCgcm0> Ml\zNlM1OTh3MkO=
K028 NHLRdWNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3vlTmlEPTB;OESgcm0> NVPqVoNzOjN2MUi1NlM>
K029 NVXmO2h4S2WubDDWbYFjcWyrdImgRZN{[Xl? NEjwdYtKSzVyPUS2JI5O M{LXbFI{PDF6NUKz
M23 Ml3iR4VtdCCYaXHibYxqfHliQYPzZZk> NFjuNnFKSzVyPUO3MlUhdk1? NFWzbogzOzRzOEWyNy=>
K033 MkewR4VtdCCYaXHibYxqfHliQYPzZZk> MnzjTWM2OD15NT61JI5O MYKyN|QyQDV{Mx?=
K008 M1L1VmZ2dmO2aX;uJGF{e2G7 MVKyOVAhdk1? M2POWVI1KGh? NWXPe25ocW6mdXPld{BIOiCjcoLld5Q> NVXXcpR1OjN2MUi1NlM>
K028 NH7QOWRHfW6ldHnvckBCe3OjeR?= MoH1NlUxKG6P M4HSS|I1KGh? MYHpcoR2[2W|IFeyJIFzemW|dB?= M2DrPFI{PDF6NUKz
K029 MoPZSpVv[3Srb36gRZN{[Xl? M4D5cVI2OCCwTR?= MY[yOEBp MorNbY5lfWOnczDHNUBienKnc4S= MVmyN|QyQDV{Mx?=
M23 MVXGeY5kfGmxbjDBd5NigQ>? MnTFNlUxKG6P MnjzNlQhcA>? NFjtR3BqdmS3Y3XzJGcyKGGwZDDHNk9OKGG{cnXzeC=> NGDjPJczOzRzOEWyNy=>
K033 MlzuSpVv[3Srb36gRZN{[Xl? M3;rZlI2OCCwTR?= MV2yOEBp M4HudIlv\HWlZYOgZUBud2Snc4SgbY5kemWjc3WgbY4hTzFicH;weYxifGmxbh?= MnrLNlM1OTh3MkO=
K008 NWDWWZVoSXCxcITvd4l{KEG|c3H5 MXexNFAhdk1? MnrPO|IhcA>? MnzVd4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? NVrMXWU3OjN2MUi1NlM>
K028 MmjSRZBweHSxc3nzJGF{e2G7 NUPuSJRjOTByIH7N MVu3NkBp M2KxNJNq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN? NYW5THlJOjN2MUi1NlM>
K029 NYn2NHZySXCxcITvd4l{KEG|c3H5 MUSxNFAhdk1? MoW1O|IhcA>? M3fsRZNq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN? MU[yN|QyQDV{Mx?=
M23 MUDBdI9xfG:|aYOgRZN{[Xl? NULQWZVXOTByIH7N NUDuS2xkPzJiaB?= NEfRUFZ{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| NXTZdVloOjN2MUi1NlM>
K033 MnflRZBweHSxc3nzJGF{e2G7 M2Xze|ExOCCwTR?= MnPpO|IhcA>? MX7zbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{ MnzTNlM1OTh3MkO=
RD MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDFVWhCUUN3ME24JI5O NWTPO4FmOjN|MEO3OFE>
Rh41 MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK1TWM2OD1zMD60JI5O NF7hbYwzOzNyM{e0NS=>
Rh18 M{PWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTZwMjDuUS=> MlfYNlM{ODN5NEG=
Rh30 M3jSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTVwNjDuUS=> M1fS[lI{OzB|N{Sx
BT-12 NF\vb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7CdI9KSzVyPUG0MlMhdk1? NXy5fFZ7OjN|MEO3OFE>
CHLA-266 M324[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXtVXI3UUN3ME2yO{4yKG6P NWi5c4gxOjN|MEO3OFE>
TC-71 M4nzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTWTWM2OD12LkWgcm0> NX;VR29mOjN|MEO3OFE>
CHLA-9 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTKV2tSUUN3ME20MlYhdk1? NWrue2pPOjN|MEO3OFE>
CHLA-10 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlj4TWM2OD13Lkegcm0> NXTYSmZSOjN|MEO3OFE>
CHLA-258 NFTme3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S4eWlEPTB;Nj60JI5O MWqyN|MxOzd2MR?=
SJ-GBM2 NIHYZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnGxTWM2OD1zMj65JI5O M{LJV|I{OzB|N{Sx
NB-1643 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2OxUGlEPTB;Nz60JI5O MUKyN|MxOzd2MR?=
NB-EBc1 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrjSnVKSzVyPUG2Mlghdk1? M3G0R|I{OzB|N{Sx
CHLA-90 NGnCTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ{LkOgcm0> NXP6flF7OjN|MEO3OFE>
CHLA-136 M1;PR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ|LkKgcm0> M1P0UFI{OzB|N{Sx
NALM-6 MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFzLkegcm0> NG\TdWgzOzNyM{e0NS=>
COG-LL-317 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK3PW5DUUN3ME20MlQhdk1? MY[yN|MxOzd2MR?=
RS4;11 NXr5fWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF|LkWgcm0> NGrBUlIzOzNyM{e0NS=>
MOLT-4 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLCVpVKSzVyPUGwMlYhdk1? M17UPVI{OzB|N{Sx
CCRF-CEM (1) M3\wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF{LkWgcm0> NFvMSpIzOzNyM{e0NS=>
CCRF-CEM (2) NHTl[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nSTWlEPTB;Nz6yJI5O MlriNlM{ODN5NEG=
Kasumi-1 NFH6R|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LqdWlEPTB;NT64JI5O NVjqSWdPOjN|MEO3OFE>
Karpas-299 NILFeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HFb2lEPTB;OT62JI5O NXjrdYd4OjN|MEO3OFE>
Ramos-RA1 NIftdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTdwNDDuUS=> NWXOOFE3OjN|MEO3OFE>
LNCaP NIDaU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHTRWFqUUN3ME24JI5O M4r1bVI{OTV{MEC0
VCaP MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j6eGlEPTB;NzDuUS=> M1fWNlI{OTV{MEC0
H1355 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILBNJpKSzVyPUWgcm0> NYXBNJlMOjNyMUKyOFg>
H157 M1zSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPPTWM2OD15IH7N M1vzelI{ODF{MkS4
H460 M2jTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRThibl2= MX6yN|AyOjJ2OB?=
IA-LM M2jCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH36NGRKSzVyPUGwJI5O NIfLWnAzOzBzMkK0PC=>
HOP-62 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;CbGlEPTB;MUGgcm0> M1jrO|I{ODF{MkS4
H23 NYHrVYNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFzIH7N NFK5[28zOzBzMkK0PC=>
H2030 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\YdmlEPTB;MUKgcm0> NFXCWm0zOzBzMkK0PC=>
H441 M4PDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF2IH7N NEHWbIszOzBzMkK0PC=>
H2212 MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj4bW9KSzVyPUG3JI5O MXSyN|AyOjJ2OB?=
SK-LU-1 NYm1OlFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli1TWM2OD1zODDuUS=> M2fXOVI{ODF{MkS4
H2009 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTvTWM2OD1zOTDuUS=> NViz[44{OjNyMUKyOFg>
H1792 M4PPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG2W29KSzVyPUKwJI5O NYjQXJNQOjNyMUKyOFg>
COR-L23 NEPze3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q2V2lEPTB;MkKgcm0> M{fDN|I{ODF{MkS4
H727 M3\HZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ6IH7N Mlm3NlMxOTJ{NEi=
H1734 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH6TWM2OD1{ODDuUS=> MorxNlMxOTJ{NEi=
H358 Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe2eWNKSzVyPUK5JI5O MWqyN|AyOjJ2OB?=
A549 NGi2VYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPtTWM2OD12MzDuUS=> MVOyN|AyOjJ2OB?=
H2122 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jXd2lEPTB;NUOgcm0> MmnJNlMxOTJ{NEi=
Calu-1 NF7iR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTV6IH7N NYjFPGtjOjNyMUKyOFg>
Calu-6 NHHiSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTZ2IH7N MlHKNlMxOTJ{NEi=
NCI-H1975 NWr5Wo0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXaOFghcA>? NIqyUWRKSzVyPUG2JI5O M4DzdFIzOTR2Nk[1
NCI-H1975 M1rWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXRZXU4OiCq MYHJR|UxRThibl2= MmHDNlIyPDR4NkW=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

お薦めの試験操作(参考用のみ)

細胞試験: [1]
+ 展開
  • 細胞株: OSA cells
  • 濃度: 0.001-1μM
  • 反応時間: 5 days
  • 実験の流れ: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: Female severe combined immune-deficient (SCID) mice
  • 製剤: In DMSO and diluted 1:10 with 20% Cremophor RH 40
  • 投薬量: 25 mg/kg/day for 3 days
  • 投与方法: Tail vein injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 40 mg/mL (109.76 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
5% DMSO+45% PEG 300+ddH2O
11mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 364.4
化学式

C20H20N4O3

CAS No. 888216-25-9
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02192541 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 9, 2014 Phase 1
NCT02637375 Withdrawn Breast Cancer University of Chicago May 2016 --
NCT02389751 Active, not recruiting Esophageal Cancer M.D. Anderson Cancer Center|Synta Pharmaceuticals Corp. April 2015 Phase 1
NCT02334319 Terminated Stage I Hypopharyngeal Squamous Cell Carcinoma|Stage I Laryngeal Squamous Cell Carcinoma|Stage I Oral Cavity Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma|Stage II Hypopharyngeal Squamous Cell Carcinoma|Stage II Laryngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma Emory University|Synta Pharmaceuticals Corp. December 2014 Phase 1
NCT02261805 Terminated Cancer|Small Cell Lung Cancer Georgetown University|Synta Pharmaceuticals Corp. October 2014 Phase 1|Phase 2
NCT02272478 Recruiting Acute Myeloid Leukaemia|Myelodysplastic Syndrome Cardiff University|Cancer Research UK October 2014 Phase 3

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Does this inhibitor inhibit both isoforms of HSP90?

  • 回答:

    We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (e.g. HSP90)信号経路図

HSP (e.g. HSP90) Inhibitors with Unique Features

相関HSP (e.g. HSP90)製品

Tags: Ganetespib (STA-9090)を買う | Ganetespib (STA-9090) ic50 | Ganetespib (STA-9090)供給者 | Ganetespib (STA-9090)を購入する | Ganetespib (STA-9090)費用 | Ganetespib (STA-9090)生産者 | オーダーGanetespib (STA-9090) | Ganetespib (STA-9090)化学構造 | Ganetespib (STA-9090)分子量 | Ganetespib (STA-9090)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID